Quadrivalent Gardasil and the bivalent Cervarix against HPV subtypes 16 and 18. 97% to 100% efficacy for preventing cervical intraepithelial neoplasia (C1N) grades 2 and 3 caused by HPV 16 or 18 in females who were not previously infected However, efficacy was only 44% in those who were infected prior to vaccination. A third HPV vaccine, Gardasil-9, an additional five high-risk subtypes (HPV 31/33/45/52/58)
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.